BioInvent International AB (publ) (STO:BINV)
Sweden flag Sweden · Delayed Price · Currency is SEK
22.30
+0.35 (1.59%)
May 4, 2026, 5:29 PM CET

STO:BINV Income Statement

Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
217.86226.544.6971.46326.1319.38
Revenue Growth (YoY)
258.30%406.86%-37.47%-78.09%1582.45%-86.85%
Gross Profit
217.86226.544.6971.46326.1319.38
Selling, General & Admin
73.273.6758.351.6150.7539.44
Research & Development
494.51504.22457.73390.43325.93258.34
Other Operating Expenses
0.42-0.12-0.1-0.02-0.08-0.23
Operating Expenses
568.12577.77515.93442.02376.6297.55
Operating Income
-350.26-351.28-471.25-370.56-50.47-278.17
Interest Expense
-0.4-0.4-0.56-0.64-0.65-0.52
Interest & Investment Income
16.319.8742.0940.619.070.26
Currency Exchange Gain (Loss)
-0.65-0.650.470.49-0.45-0.03
EBT Excluding Unusual Items
-335.02-332.46-429.24-330.1-42.5-278.44
Pretax Income
-335.02-332.46-429.24-330.1-42.5-278.44
Income Tax Expense
0.430.40.140.2--
Net Income
-335.45-332.86-429.38-330.3-42.5-278.44
Net Income to Common
-335.45-332.86-429.38-330.3-42.5-278.44
Shares Outstanding (Basic)
666666666254
Shares Outstanding (Diluted)
666666666254
Shares Change (YoY)
0.05%-0.06%6.90%13.59%88.61%
EPS (Basic)
-5.10-5.06-6.53-5.02-0.69-5.14
EPS (Diluted)
-5.10-5.06-6.53-5.02-0.69-5.14
Free Cash Flow
-265.69-255.02-390.5-355-53.6-259.1
Free Cash Flow Per Share
-4.04-3.88-5.93-5.40-0.87-4.78
Gross Margin
100.00%100.00%100.00%100.00%100.00%100.00%
Operating Margin
-160.77%-155.09%-1054.58%-518.54%-15.48%-1435.02%
Profit Margin
-153.98%-146.96%-960.87%-462.22%-13.03%-1436.46%
Free Cash Flow Margin
-121.96%-112.59%-873.88%-496.77%-16.44%-1336.68%
EBITDA
-338.82-339.58-460.01-361.29-41.91-269.79
EBITDA Margin
-155.52%-149.93%---12.85%-
D&A For EBITDA
11.4411.6911.249.268.568.37
EBIT
-350.26-351.28-471.25-370.56-50.47-278.17
EBIT Margin
-160.77%-155.09%---15.48%-
Source: S&P Global Market Intelligence. Standard template. Financial Sources.